

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 976 328 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
02.02.2000 Bulletin 2000/05

(21) Application number: 99114117.7

(22) Date of filing: 19.07.1999

(51) Int. Cl.⁷: **A01N 51/00**, A01N 47/40,
A01N 43/88, A01N 43/78,
A01N 43/64, A01N 43/54,
A01N 43/50, A01N 43/40,
A01N 43/08, A01N 37/52,
A01N 37/34, A01N 25/02

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 27.07.1998 JP 21087598
28.10.1998 JP 30696098

(71) Applicant:
Sumitomo Chemical Company, Limited
Chuo-ku Osaka 541-8550 (JP)

(72) Inventors:
• Sembo, Satoshi
Takarazuka-shi, Hyogo (JP)
• Makita, Mitsuyasu
Nishinomiyashi, Hyogo (JP)

(74) Representative:
VOSSIUS & PARTNER
Siebertstrasse 4
81675 München (DE)

(54) **Ectoparasite controlling agent for animals**

(57) An ectoparasite-controlling agent for animals comprising 0.1 to 20% by weight of the neonocotinoid compounds defined in the specification and 10 to 95% by weight of a glycol or glycol monoalkyl ether has an excellent effectiveness by the application methods such as spot-on and pour-on application.

EP 0 976 328 A2

Description


[0001] The present invention relates to ectoparasite controlling agents, and more specifically relates to an excellent ectoparasite controlling agent for animals which is used for regional application methods such as spot-on or pour-on application and a method for controlling ectoparasites of animals.

[0002] Heretofore, as an application method to control harmful pests that injure domestic animals such as pets and farm animals, particularly ectoparasites such as fleas (Pulicidae) and lice (Anoplura), methods of application recognized as spot-on and pour-on applications have been known, and because these methods of applications have been elementary, they are utilized in the concerning ectoparasite controlling.


[0003] However, it was not common to have the active ingredients contained in the ectoparasite controlling agents to be always sufficiently effective.

[0004] The present invention provides an ectoparasite controlling agent for animals having an ability to exert an excellent efficacy against ectoparasites from spot-on or pour-on applications, with the incorporation of a neonicotinoid compound and a glycol or a specific glycol derivative, as well as from the specialized mixing ratio of that incorporation.


[0005] More specifically, the present invention is an ectoparasite controlling agent for animals (hereinafter, the present agent(s)) which is a liquid formulation comprising 10 to 95% by weight of a glycol or glycol monoalkyl ether (e.g. C₁₋₄ alkyl ether) and 0.1 to 20% by weight of the neonicotinoid compound given in the following formula (1), (2) or (3) (hereinafter, the present compound(s)):



(1)



(2)



(3)

(wherein, A represents a 6-chloro-3-pyridyl, 2-chloro-5-thiazolyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, 5-methyltetrahydrofuran-3-yl, 3-pyridyl, 6-bromo-3-pyridyl, 3-cyanophenyl, 2-methyl-5-thiazolyl, 2-phenyl-5-thiazolyl or 2-bromo-5-thiazolyl group;

R₁ represents a hydrogen atom, methyl, ethyl, formyl or acetyl group;

R₂ represents a methyl, amino, methylamino, N,N-dimethylamino, ethylamino, N,N-diethylamino, N-methyl-N-ethylamino, 1-pyrrolidinyl, (6-chloro-3-pyridyl)methylamino or N-methyl-N-(6-chloro-3-pyridyl)methylamino group;

R₃ represents a methyl, ethyl, propyl, propenyl or propynyl group;

X represents a nitrogen atom or CH group;

Y represents a cyano, nitro or trifluoroacetyl group;

Z represents a NH group or sulfur atom;

D represents an oxygen atom or -N(CH₃)- group;

m represents an integer of 0 or 1; and

n represents an integer of 2 or 3)

as well as, a method for controlling ectoparasites of animals.

[0006] The present compounds are known as active ingredients for pesticides, and described in, for example, US-A-5,532,365, US-A-4,742,060, US-A-4,849,432, US-A-5,034,404, US-A-5,750,548, US-A-5,304,566 and EP-A-0 428 941. The present compound is comprised from 0.1 to 20% by weight, preferably from 1 to 15 % by weight, and more preferably from 5 to 10% by weight in the present agent.

[0007] As the compound given in the formula (1), for example, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamide, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylenediamine, 1-(6-chloro-3-pyridyl)methyl-3-methyl-2-cyanoguanidine, 1-(6-chloro-3-pyridyl)methyl-1,3-dimethyl-2-cyanoguanidine, 1-(6-chloro-3-pyridyl)methyl-1-ethyl-3-methyl-2-cyanoguanidine, 1-(6-chloro-3-pyridyl)methyl-1,3-dimethyl-3-(6-chloro-3-pyridyl)methyl-2-cyanoguanidine, 1-(6-chloro-3-pyridyl)methyl-3-methyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-3,3-dimethyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-1-methyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-1,3-

dimethyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-3-ethyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-3-(6-chloro-3-pyridyl)methyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-3-methyl-2-trifluoroacetylguanidine, 1-(6-chloro-3-pyridyl)methyl-1-ethyl-3-methyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-1,3,3-trimethyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-1-ethyl-2-nitroguanidine, 1-(3-pyridyl)methyl-3-methyl-2-nitroguanidine, 1-(6-bromo-3-pyridyl)methyl-3-methyl-2-nitroguanidine, 1-(2-chloro-5-thiazolyl)methyl-3-methyl-2-nitroguanidine, 1-(3-cyanophenyl)-3-methyl-2-nitroguanidine, 1-(4-chlorophenyl)methyl-3-methyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-3,3-dimethyl-1-formyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-3,3-dimethyl-1-acetyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)-3-methyl-2-cyanoguanidine, 1-(2-chloro-5-thiazolyl)methyl-3,3-dimethyl-2-nitroguanidine, 1-(2-chloro-5-thiazolyl)methyl-1-ethyl-3-methyl-2-nitroguanidine, 1-(2-chloro-5-thiazolyl)methyl-1-acetyl-3,3-dimethyl-2-nitroguanidine, 1-(6-chloro-3-pyridyl)methyl-1-ethyl-2-trifluoroacetylguanidine, 1-(2-chloro-5-thiazolyl)methyl-1,3-dimethyl-2-nitroguanidine, 1-(2-chloro-5-thiazolyl)methyl-1-methyl-2-nitroguanidine, 1-(5-thiazolyl)methyl-3-methyl-2-nitroguanidine, 1-(2-methyl-5-thiazolyl)methyl-3,3-dimethyl-2-nitroguanidine, 1-(2-methyl-5-thiazolyl)methyl-3-methyl-2-nitroguanidine, 1-(2-phenyl-5-thiazolyl)methyl-3-methyl-2-nitroguanidine, 1-(2-chloro-5-thiazolyl)methyl-3,3-diethyl-2-nitroguanidine, 1-(2-chloro-5-thiazolyl)methyl-3-methyl-3-ethyl-2-nitroguanidine, 1-(2-chloro-5-thiazolyl)methyl-3-(1-pyrrolidinyl)-2-nitroguanidine, 1-(2-chloro-5-thiazolyl)methyl-1,3,3-trimethyl-2-nitroguanidine, 1-(2-bromo-5-thiazolyl)methyl-3-methyl-2-nitroguanidine, 1-(2-bromo-5-thiazolyl)methyl-3,3-dimethyl-2-nitroguanidine, 1-(2-chloro-5-thiazolyl)methyl-3-methyl-2-cyanoguanidine, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine or 1-(tetrahydrofuran-2-yl)methyl-3-methyl-2-nitroguanidine is suitable.

[0008] As the compound given in the formula (2), for example, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidine-imine or 1-[(6-chloro-3-pyridyl)methyl]-N-nitrotetrahydropyrimidine-2-imine is suitable.

[0009] As the compound given in the formula (3), for example, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine, 3,5-dimethyl-1-[(6-chloro-3-pyridyl)methyl]-N-nitrohexahydro-1,3,5-triazine-2-imine, 3,5-dimethyl-1-[(2-chloro-5-thiazolyl)methyl]-2-nitroiminohexahydro-1,3,5-triazine, 3-ethyl-5-methyl-1-[(6-chloro-3-pyridyl)methyl]-N-nitrohexahydro-1,3,5-triazine-2-imine, 3-n-propyl-5-methyl-1-[(6-chloro-3-pyridyl)methyl]-N-nitrohexahydro-1,3,5-triazine-2-imine, 3-n-propyl-5-methyl-1-[(2-chloro-5-thiazolyl)methyl]-N-nitrohexahydro-1,3,5-triazine-2-imine, 3-(2-propenyl)-5-methyl-1-[(6-chloro-3-pyridyl)methyl]-N-nitrohexahydro-1,3,5-triazine-2-imine or 3-(2-propynyl)-5-methyl-1-[(6-chloro-3-pyridyl)methyl]-N-nitrohexahydro-1,3,5-triazine-2-imine is suitable.

[0010] As the glycol or glycol monoalkyl ether, for example, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, hexamethylene glycol, 1,3-butanediol, 3-methyl-1,3-butanediol, 2-methyl-1,3-propanediol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monotertiarybutyl ether, dipropylene glycol monomethyl ether or 3-methoxy-3-methyl-1-butanol is suitable. The present agent comprises the glycol from 10 to 95% by weight, preferably from 30 to 90% by weight, and more preferably from 50 to 80% by weight.

[0011] More specifically, for the present compound and the glycol in the present agent, the following are examples of suitable combinations:

(E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamide and ethylene glycol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and ethylene glycol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and ethylene glycol, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and ethylene glycol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and ethylene glycol, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamide and diethylene glycol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and diethylene glycol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and diethylene glycol, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and diethylene glycol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and diethylene glycol, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamide and triethylene glycol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and triethylene glycol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and triethylene glycol, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and triethylene glycol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and triethylene glycol, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamide and propylene glycol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and propylene glycol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and propylene glycol, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and propylene glycol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and propylene glycol, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamide and dipropylene glycol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and dipropylene glycol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and dipropylene glycol, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and dipropylene glycol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and dipropylene glycol, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamide and tripropylene glycol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and tripropylene glycol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and

tripropylene glycol, 3-[(6-chloro-3-pyridyl)methyl-N-cyano-2-thiazolidineimine and tripropylene glycol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and tripropylene glycol, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine and hexamethylene glycol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and hexamethylene glycol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and hexamethylene glycol, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and hexamethylene glycol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and hexamethylene glycol, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine and 1,3-butanediol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and 1,3-butanediol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and 1,3-butanediol, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and 1,3-butanediol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and 1,3-butanediol, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine and 3-methyl-1,3-butanediol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and 3-methyl-1,3-butanediol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and 3-methyl-1,3-butanediol, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and 3-methyl-1,3-butanediol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and 3-methyl-1,3-butanediol, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine and 2-methyl-1,3-propanediol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and 2-methyl-1,3-propanediol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and 2-methyl-1,3-propanediol, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and 2-methyl-1,3-propanediol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and 2-methyl-1,3-propanediol, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine and ethylene glycol monomethyl ether, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and ethylene glycol monomethyl ether, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and ethylene glycol monomethyl ether, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and ethylene glycol monomethyl ether, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and ethylene glycol monomethyl ether, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine and ethylene glycol monoethyl ether, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and ethylene glycol monoethyl ether, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and ethylene glycol monoethyl ether, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and ethylene glycol monoethyl ether, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and ethylene glycol monoethyl ether, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine and ethylene glycol monobutyl ether, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and ethylene glycol monobutyl ether, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and ethylene glycol monobutyl ether, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and ethylene glycol monobutyl ether, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and ethylene glycol monobutyl ether, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine and propylene glycol monomethyl ether, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and propylene glycol monomethyl ether, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and propylene glycol monomethyl ether, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and propylene glycol monomethyl ether, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and propylene glycol monomethyl ether, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine and propylene glycol monotertiarybutyl ether, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and propylene glycol monotertiarybutyl ether, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and propylene glycol monotertiarybutyl ether, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and propylene glycol monotertiarybutyl ether, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and propylene glycol monotertiarybutyl ether, (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine and 3-methoxy-3-methyl-1-butanol, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylidenediamine and 3-methoxy-3-methyl-1-butanol, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine and 3-methoxy-3-methyl-1-butanol, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine and 3-methoxy-3-methyl-1-butanol, 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine and 3-methoxy-3-methyl-1-butanol and so on.

[0012] The present agent is a liquid formulation comprising 10 to 95% by weight of a glycol or glycol monoalkyl ether and 0.1 to 20% by weight of the present compound, and may comprise, optionally, for example, liquid caters such as C₁₋₄ alcohols (e.g. methanol, ethanol, isopropyl alcohol, tert-butyl alcohol); propylene carbonate, N-methyl-2-pyrrolidone and water. Said liquid carrier is preferably the solvent that is miscible with a glycol or glycol monoalkyl ether and the amount of the solvent is usually 3 to 85% by weight or less, preferably 3 to 70% by weight or less in case that the solvent is utilized. The present agent may further comprise auxiliaries. Examples of the auxiliaries include anti-oxidants such as BHT and BHA; emulsifiers such as sorbitan monooleate, sorbitan monolaurate, caprylic acid monoglyceride,

capric acid monoglyceride, isostearic acid monoglyceride and propylene glycol monocaprylate; and oxyacid esters such as triethyl citrate.

[0013] The present agent may also comprise, optionally, active ingredients other than the present compound.

[0014] The active ingredients are, for example, pyrethroid compounds such as permethrin, phenothrin, allethrin, pyrethrin, cyphenothrin, cyfluthrin, fenvalerate, fenpropathrin and transfluthrin; organophosphorus compounds such as dichlorvos, tetrachlorvinphos, fenthion, chlorpyrifos and diazinon; carbamate compounds such as propoxur, carbaryl, metoxadiazon and fenobucarb; chitin-synthesis inhibiting substances such as lufenuron, chlorfluazuron, hexafluoruron, cyromazine and 1-(2,6-difluorobenzoyl)-3-[2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]urea; juvenile hormone analogues such as methoprene, hydroprene and fenoxycarb; N-phenylpyrazole compounds; endoparasite controlling substances for animals such as milbemycin, abamectin and avermectin; pest repelling compounds such as N,N-diethyl-m-toluamide (DEET), limonene, linalool, citronellal, menthol, menthone, hinokitiol, geraniol, eucalyptol, indoxacarb, carane-3,4-diol, orange oil, citronella oil, lemon oil, lemongrass oil, cinnamon oil, peppermint oil, spearmint oil and hyssop oil; or synergists such as piperonyl butoxide (PBO), octachlorodipropyl ether (S-421), N-(2-ethylhexyl)bicyclo[2.2.1]hept-5-ene-2,3-dicarboximide, isobornyl thiocyanatoacetate (IBTA) and N-(2-ethylhexyl)-1-isopropyl-4-methylbicyclo[2.2.2]oct-5-ene-2,3-dicarboximide are suitable.

[0015] The present agent usually controls ectoparasites for animals efficiently by employing onto animals by regional application methods such as spot-on application and pour-on application.

[0016] The spot-on application is a well-known method for controlling ectoparasites by dropping a liquid agent onto a skin at the back of blade bone of animal body.

[0017] The pour-on application is also a well-known method for controlling ectoparasites by pouring a liquid agent along the back line of animal body and having the liquid agent spread on the surface of the animal body.

[0018] The dosage of the present agent is usually about 0.01 to 10mL and the dosage of the present compound is usually about 0.1 to 300mg per 1kg of animal weight.

[0019] For the present invention, and as the pests that are effectively controlled, suitable ectoparasites of farm animals such as cows and sheep, as well as pets such as dogs and cats, include, for example, Diptera such as *Musca hervei*, *Musca bezzii*, *Haematobia irritans*, *Simulium iwatens*, *Culicoides oxystoma*, *Tabanus chrysurus*, *Culex pipiens* (common mosquito) and *Aedes albopictus*; Anoplura (lice) such as *Haematopinus eurysternus* and *Damalinia ovis*; and Siphonaptera such as *Ctenocephalides felis* (cat flea), *Ctenophalides canis* (dog flea) and *Xenopsylla cheopis*.

[0020] Furthermore, the objective animals that the present invention is employed upon, include the farm animals and pets mentioned above, and others, for example, Rodentia such as mice, rats, hamsters and squirrels; Lagomorpha such as rabbits; Carnivora such as ferrets; birds such as ducks, chickens, doves; and the like.

Examples

[0021] The present invention is explained with the examples in detail below.

Formulation example 1

[0022] Five parts by weight of 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine (hereinafter, Compound A), 50 parts by weight of hexamethylene glycol and 45 parts by weight of isopropanol are mixed to obtain a formulation.

Formulation example 2

[0023] Five parts by weight of Compound A, 50 parts by weight of propylene glycol monomethyl ether and 45 parts by weight of dipropylene glycol are mixed to obtain a formulation.

Formulation example 3

[0024] Five parts by weight of Compound A, 0.5 parts by weight of pyriproxyfen, 50 parts by weight of propylene glycol monomethyl ether and 44.5 parts by weight of isopropanol are mixed to obtain a formulation.

Formulation example 4

[0025] Five parts by weight of Compound A, 85 parts by weight of propylene glycol monomethyl ether and 10 parts by weight of d-limonene are mixed to obtain a formulation.

EP 0 976 328 A2

Test example 1

[0026] Formulations 1 through 7 were obtained by dissolving 5 parts by weight of Compound A into a previously prepared mixed solution of tripropylene glycol (hereinafter, TPG) and isopropanol (hereinafter, IPA) wherein the parts by weight of each preparation of 7 possibilities is 0:95, 10:85, 30:65, 50:45, 70:25, 80:15 and 95:0.

[0027] One fiftieths milliliters (0.02mL) was dropped onto the neck area epidermis of a mouse (weight: about 30g). Said mouse was hold and fastened with a metal net, and placed into a 900mL glass canister. Twenty adult cat fleas were deposited into said canister so the mouse is infested. One day after infestation, the mortality was examined. Each was repeated thrice. The results are given in table 1.

Table 1

Test #	Formulation	TPG/IPA (wt/wt)	Compound A/ TPG (wt/wt)	Mortality of Cat fleas (%)
1-1(Comparative)	1	0/95	5/0	38.3
1-2	2	10/85	5/10	55.0
1-3	3	30/65	5/30	75.0
1-4	4	50/45	5/50	80.0
1-5	5	70/25	5/70	93.3
1-6	6	80/15	5/80	75.0
1-7	7	95/0	5/95	60.0

Test example 2

[0028] Ten parts by weight of Compound A was mixed with 90 parts by weight of diethylene glycol monoethyl ether and dissolved to afford a spot-on formulation.

[0029] Thirty cat flea adults were deposited on a cat (weight: 3.4kg) and an elizabethan collar was put on the neck of the cat the day before application of the above formulation. Two fiftihs milliliters (0.4mL) of the above spot-on formulation was spread onto the skin at the back of blade bone of the cat. Then, one day and three days after application, the number of infested fleas was counted by using a comb for gathering fleas. All the counted fleas were re-deposited on the cat after counting.

[0030] In addition, as a blank, cat fleas were deposited on a cat without application of the formulation by the same method as above, the number of the cat fleas was observed and controlling ratio was calculated by the following formula:

$$\text{Controlling ratio (\%)} = (C - T) \div C \times 100$$

C : Infesting ratio of fleas in the case without application

T : Infesting ratio of fleas in the case with application of the formulation




Each was repeated twice and the result are given in table 2.

Table 2

		One day after application	Three days after application
treated with spot-on formulation	Infesting ratio	3.3	1.7
	Controlling ratio	95.6	97.5
blank (no treatment)	Infesting ratio	75.0	66.7

Claims

1. An ectoparasite-controlling agent for animals which is a liquid formulation comprising 0.1 to 20% by weight of the neonicotinoid compound given in the following formula (1), (2) or (3) and 10 to 95% of a glycol or glycol monoalkyl ether:



wherein, A represents a 6-chloro-3-pyridyl, 2-chloro-5-thiazolyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, 5-methyltetrahydrofuran-3-yl, 3-pyridyl, 6-bromo-3-pyridyl, 3-cyanophenyl, 2-methyl-5-thiazolyl, 2-phenyl-5-thiazolyl or 2-bromo-5-thiazolyl group; R₁ represents a hydrogen atom, methyl, ethyl, formyl or acetyl group; R₂ represents a methyl, amino, methylamino, N,N-dimethylamino, ethylamino, N,N-diethylamino, N-methyl-N-ethylamino, 1-pyrrolidyl, (6-chloro-3-pyridinyl)methylamino or N-methyl-N-(6-chloro-3-pyridinyl)methylamino group; R₃ represents a methyl, ethyl, propyl, propenyl or propynyl group; X represents a nitrogen atom or CH group; Y represents a cyano, nitro or trifluoroacetyl group; Z represents a NH group or sulfur atom; D represents an oxygen atom or -N(CH₃)- group; m represents an integer of 0 or 1; and n represents an integer of 2 or 3.

2. An ectoparasite-controlling agent according to claim 1, wherein the glycol or glycol monoalkyl ether is at least one selected from ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, hexamethylene glycol, 1,3-butanediol, 3-methyl-1,2-butanediol, 2-methyl-1,3-propanediol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monotertiarybutyl ether, dipropylene glycol monomethyl ether and 3-methoxy-3-methyl-1-butanol.
3. An ectoparasite-controlling agent according to claim 1 or 2, which further comprises a solvent that is miscible with the glycol or glycol monoalkyl ether.
4. An ectoparasite-controlling agent according to claim 1 or 2, which further comprises a solvent selected from C₁₋₄ alcohols, propylene carbonate, N-methyl-2-pyrrolidone and water.
5. An ectoparasite-controlling agent according to any of claims 1, wherein the neonicotinoid compound is the compound given in formula (1).
6. An ectoparasite-controlling agent according to claim 1, wherein the neonicotinoid compound is given in general formula (1) and the substituent A is a 6-chloro-3-pyridyl, 2-chloro-5-thiazolyl, tetrahydrofuran-2-yl or tetrahydrofuran-3-yl group.
7. An ectoparasite-controlling agent according to claim 1, wherein the neonicotinoid compound is (E)-N¹-[(6-chloro-3-pyridyl)methyl]-N²-cyano-N¹-methylacetamidine, N-[(6-chloro-3-pyridyl)methyl]-N-ethyl-N'-methyl-2-nitro-1,1-ethylenediamine, 1-(tetrahydrofuran-3-yl)methyl-3-methyl-2-nitroguanidine, 3-[(6-chloro-3-pyridyl)methyl]-N-cyano-2-thiazolidineimine or 3-[(2-chloro-5-thiazolyl)methyl]-5-methyl-4-nitroiminotetrahydro-1,3,5-oxadiazine.
8. An ectoparasite-controlling method for animals which comprises applying the ectoparasite-controlling agent of claim 1 to the body surface of the animals.
9. A use of the agent of claim 1 for ectoparasite-controlling of animals.

EP 0 976 328 A2

10. A use of the ectoparasite-controlling agent of claim 1 for spot-on or pour-on application for animals.

5

10

15

20

25

30

35

40

45

50

55

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 976 328 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
16.08.2000 Bulletin 2000/33

(43) Date of publication A2:
02.02.2000 Bulletin 2000/05

(21) Application number: 99114117.7

(22) Date of filing: 19.07.1999

(51) Int. Cl.⁷: **A01N 51/00**, A01N 47/40,
A01N 43/88, A01N 43/78,
A01N 43/64, A01N 43/54,
A01N 43/50, A01N 43/40,
A01N 43/08, A01N 37/52,
A01N 37/34, A01N 25/02

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 27.07.1998 JP 21087598
28.10.1998 JP 30696098

(71) Applicant:
Sumitomo Chemical Company, Limited
Chuo-ku Osaka 541-8550 (JP)

(72) Inventors:
• Sembo, Satoshi
Takarazuka-shi, Hyogo 665-0043 (JP)
• Makita, Mitsuyasu
Nishinomiya-shi, Hyogo 663-8001 (JP)

(74) Representative:
VOSSIUS & PARTNER
Siebertstrasse 4
81675 München (DE)

(54) **Ectoparasite controlling agent for animals**

(57) An ectoparasite-controlling agent for animals comprising 0.1 to 20% by weight of the neonocotinoid compounds defined in the specification and 10 to 95% by weight of a glycol or glycol monoalkyl ether has an excellent effectiveness by the application methods such as spot-on and pour-on application.

EP 0 976 328 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 11 4117

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 98 17277 A (DERRIEU GUY ;VIRBAC SA (FR); BEUVRY VINCENT (FR); GOZLAN THIERRY ()) 30 April 1998 (1998-04-30) * page 7, line 10-23 * * page 12, line 7-11; examples 11,12 *	1-10	A01N51/00 A01N47/40 A01N43/88 A01N43/78 A01N43/64 A01N43/54 A01N43/50 A01N43/40 A01N43/08 A01N37/52 A01N37/34 A01N25/02
P,X	WO 98 42191 A (JULIA BRUNO ;MERIAL SAS (FR); ETCHEGARAY JEAN PIERRE (FR); JEANNIN) 1 October 1998 (1998-10-01) * page 2, line 18-21 * * page 3, line 30 - page 4, line 3 * * page 7, line 28 - page 8, line 2 *	1-10	
E	WO 99 41987 A (BAYER AG ;HORN KARIN (DE); SIRINYAN KIRKOR (DE); SONNECK RAINER (D)) 26 August 1999 (1999-08-26) * page 1, line 18 - page 2, line 18 * * page 14, line 1-9 *	1-10	
X	WO 97 40692 A (CIBA GEIGY AG ;SENN ROBERT (CH); MAIENFISCH PETER (CH); WYSS PETER) 6 November 1997 (1997-11-06) * page 1, paragraphs 3,4 * * page 19, paragraph 2; example F2 *	1-8	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A01N
Y		9,10	
X	EP 0 682 869 A (BAYER AG) 22 November 1995 (1995-11-22) * page 6, line 46 - page 7, line 29; examples 6,A *	1-10	
Y	WO 97 37544 A (BAYER AG ;SIRINYAN KIRKOR (DE); HEUKAMP ULRICH (DE); DORN HUBERT ()) 16 October 1997 (1997-10-16) * page 1, line 18-30 * * page 8, line 8-17 *	1-10	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 21 June 2000	Examiner Klaver, J
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (02/02) (P04C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 11 4117

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	ARTHER R ET AL: "Efficacy of imidacloprid for removal and control of fleas (Ctenocephalides felis) in dogs" AMERICAN JOURNAL OF VETERINARY RESEARCH, vol. 58, no. 8, August 1997 (1997-08), pages 848-850, XP002115500 ISSN: 0002-9645 * page 848, column 2, paragraph 3 *	1-10	
Y	EP 0 061 208 A (JANSSEN PHARMACEUTICA NV) 29 September 1982 (1982-09-29) * page 4, line 23 - page 6, line 8 *	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 21 June 2000	Examiner Klaver, J
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (03.02.92) (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 11 4117

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-06-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9817277 A	30-04-1998	EP 0836851 A	22-04-1998
		AU 5750198 A	15-05-1998
WO 9842191 A	01-10-1998	FR 2761232 A	02-10-1998
		AU 7050898 A	20-10-1998
		EP 0971589 A	19-01-2000
WO 9941987 A	26-08-1999	DE 19807630 A	26-08-1999
		AU 2523099 A	06-09-1999
WO 9740692 A	06-11-1997	AU 718566 B	13-04-2000
		AU 2699297 A	19-11-1997
		BR 9709181 A	03-08-1999
		CA 2251914 A	06-11-1997
		CN 1220578 A	23-06-1999
		EP 0900024 A	10-03-1999
EP 0682869 A	22-11-1995	DE 4417742 A	23-11-1995
		AU 696581 B	17-09-1998
		AU 2014495 A	30-11-1995
		CA 2149594 A	21-11-1995
		CZ 9501309 A	13-05-1998
		FI 952421 A	21-11-1995
		HU 71902 A	28-02-1996
		JP 8092091 A	09-04-1996
		NO 951993 A	21-11-1995
		NZ 272141 A	28-10-1996
		PL 308664 A	27-11-1995
		SK 66395 A	06-12-1995
		ZA 9504107 A	19-01-1996
WO 9737544 A	16-10-1997	DE 19613334 A	09-10-1997
		AU 719963 B	18-05-2000
		AU 2504797 A	29-10-1997
		BR 9708487 A	03-08-1999
		CA 2250825 A	16-10-1997
		CN 1214611 A	21-04-1999
		CZ 9803187 A	17-02-1999
		EP 0892606 A	27-01-1999
		PL 329126 A	15-03-1999
		SK 138098 A	13-04-1999
EP 0061208 A	29-09-1982	AU 569187 B	21-01-1988
		AU 5167185 A	15-05-1986
		AU 8124682 A	23-09-1982
		DK 114282 A	17-09-1982

EPO FORM P459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 11 4117

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-06-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0061208 A		FI 820881 A	17-09-1982
		FR 2504779 A	05-11-1982
		GB 2094626 A, B	22-09-1982
		GR 76362 A	06-08-1984
		IE 52293 B	02-09-1987
		JP 57165306 A	12-10-1982
		NO 820845 A	17-09-1982
		NZ 199904 A	31-05-1985
		PT 74581 A	01-04-1982

EPO FORM P459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82